Nyxoah Accelerates International Growth with New Production Line at LégiaPark
Belgian medtech scale-up Nyxoah, a leader in neuromodulation treatments for obstructive sleep apnea (OSA), is taking a major step in its international growth strategy with the launch of a new production line at LégiaPark.
Developed in collaboration with ABN Cleanroom Technology NV, the facility features state-of-the-art cleanroom technology, and ABN has also opened a local office at LégiaPark, strengthening the regional life sciences ecosystem.
“This investment strengthens our ability to meet growing global demand and reinforces our confidence in creating long-term value,” says Olivier Taelman, CEO of Nyxoah.
The expansion demonstrates the strength of Belgium’s life sciences ecosystem, providing Nyxoah’s teams with access to advanced infrastructure and a collaborative environment in the Liège region.
With this new production line, Nyxoah continues to scale operations globally while anchoring innovation firmly in Belgium — combining ambition and local expertise.